JP7709456B2 - 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法 - Google Patents

肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法

Info

Publication number
JP7709456B2
JP7709456B2 JP2022562676A JP2022562676A JP7709456B2 JP 7709456 B2 JP7709456 B2 JP 7709456B2 JP 2022562676 A JP2022562676 A JP 2022562676A JP 2022562676 A JP2022562676 A JP 2022562676A JP 7709456 B2 JP7709456 B2 JP 7709456B2
Authority
JP
Japan
Prior art keywords
lenvatinib
miv
liver
cancer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522325A (ja
JP2023522325A5 (https=
Inventor
オーベルク，フレドリク
Original Assignee
メディヴィル・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディヴィル・アクチエボラーグ filed Critical メディヴィル・アクチエボラーグ
Publication of JP2023522325A publication Critical patent/JP2023522325A/ja
Publication of JP2023522325A5 publication Critical patent/JP2023522325A5/ja
Application granted granted Critical
Publication of JP7709456B2 publication Critical patent/JP7709456B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022562676A 2020-04-15 2021-04-14 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法 Active JP7709456B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2050430-4 2020-04-15
SE2050430 2020-04-15
PCT/SE2021/050338 WO2021211039A1 (en) 2020-04-15 2021-04-14 Miv-818/lenvatinib combination therapy for liver cancer

Publications (3)

Publication Number Publication Date
JP2023522325A JP2023522325A (ja) 2023-05-30
JP2023522325A5 JP2023522325A5 (https=) 2024-03-22
JP7709456B2 true JP7709456B2 (ja) 2025-07-16

Family

ID=78084457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562676A Active JP7709456B2 (ja) 2020-04-15 2021-04-14 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法

Country Status (13)

Country Link
US (1) US20240024342A1 (https=)
EP (1) EP4135849B1 (https=)
JP (1) JP7709456B2 (https=)
KR (1) KR20230003522A (https=)
CN (1) CN115485029A (https=)
AU (1) AU2021255043B9 (https=)
CA (1) CA3174940A1 (https=)
ES (1) ES3027841T3 (https=)
HR (1) HRP20250669T1 (https=)
HU (1) HUE071473T2 (https=)
PL (1) PL4135849T3 (https=)
TW (1) TW202200140A (https=)
WO (1) WO2021211039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
TW202444368A (zh) * 2023-03-30 2024-11-16 瑞典商米迪維艾克提伯拉公司 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526677A (ja) 2014-08-25 2017-09-14 メディヴィル・アクチエボラーグ 癌の処置のためのウリジンのジオキソラン類似体
JP2019507764A (ja) 2016-03-02 2019-03-22 メディヴィル・アクチエボラーグ ソラフェニブ又はレゴラフェニブとトロキサシタビンのホスホロアミデートプロドラッグを用いた併用療法
JP2022542238A (ja) 2019-07-26 2022-09-30 エスパーヴィタ セラピューティクス，インコーポレイテッド 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019134940A (ru) * 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526677A (ja) 2014-08-25 2017-09-14 メディヴィル・アクチエボラーグ 癌の処置のためのウリジンのジオキソラン類似体
JP2019507764A (ja) 2016-03-02 2019-03-22 メディヴィル・アクチエボラーグ ソラフェニブ又はレゴラフェニブとトロキサシタビンのホスホロアミデートプロドラッグを用いた併用療法
JP2022542238A (ja) 2019-07-26 2022-09-30 エスパーヴィタ セラピューティクス，インコーポレイテッド 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸

Also Published As

Publication number Publication date
HRP20250669T1 (hr) 2025-08-01
EP4135849A1 (en) 2023-02-22
JP2023522325A (ja) 2023-05-30
US20240024342A1 (en) 2024-01-25
EP4135849B1 (en) 2025-03-19
EP4135849A4 (en) 2024-04-17
WO2021211039A1 (en) 2021-10-21
ES3027841T3 (en) 2025-06-17
AU2021255043B2 (en) 2025-06-05
KR20230003522A (ko) 2023-01-06
HUE071473T2 (hu) 2025-09-28
PL4135849T3 (pl) 2025-07-14
CN115485029A (zh) 2022-12-16
AU2021255043A1 (en) 2022-11-03
EP4135849C0 (en) 2025-03-19
AU2021255043B9 (en) 2025-07-10
CA3174940A1 (en) 2021-10-21
TW202200140A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
KR102703122B1 (ko) 소라페닙 또는 레고라페닙과 트록사시타빈의 포스포라미데이트 전구약물의 병용 요법
JP7709456B2 (ja) 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法
Peng et al. Hepatic artery infusion of floxuridine in combination with systemic chemotherapy for pancreatic cancer liver metastasis: a propensity score-matched analysis in two centers
Huang et al. Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE
HK40081068A (en) Miv-818/lenvatinib combination therapy for liver cancer
Said et al. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver
HK40040637B (zh) 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
HK40040637A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
BR112018067387B1 (pt) Uso de um agente terapêutico
HK40000353A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40000353B (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
Melichar et al. Hepatic arterial infusion in liver tumors of unknown, uncertain or unusual primary: single-center experience
Yamashita et al. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced
JPWO2017030146A1 (ja) 胆道癌治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250704

R150 Certificate of patent or registration of utility model

Ref document number: 7709456

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150